Ingersoll Rand has successfully finalized a definitive agreement to acquire 100% of ILC Dover from New Mountain Capital, marking a transformative expansion into the life sciences sector. This strategic transaction establishes a dedicated life sciences platform within the group’s Precision and Science Technologies (P&ST) segment, consolidating the target’s expertise with the group’s existing brands to create a $700 million revenue vertical. The strategic rationale for the move centers on the convergence of the target’s innovative single-use biopharma solutions with the group’s established liquid handling and positive displacement pump technologies. By incorporating the target’s established direct channels and deep connectivity with over 1,000 biopharma and medical device customers, the organization significantly increases its addressable market in highly fragmented growth segments. The partnership focuses on leveraging the group’s demand generation capabilities to drive cross-selling opportunities across its broader industrial product lines, such as specialized compressors and vacuum solutions. This integration reinforces the group’s position as a primary enabler of advanced medical therapy production and pharmaceutical innovation, providing the operational depth required to achieve high-single-digit returns on invested capital through standardized industrial excellence.

ILC DOVER, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 10.3x average currently observed in the Industry & Manufacturing sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.